The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

II.b

ARDS - Acute lung injury

Publications

Bianco A, Mari PV, Larici AR, Lucchini M, Nociti V, Losavio FA, De Fino C, Cicchetti G, Coraci D, Richeldi L, Mirabella M

Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients.

Multiple sclerosis and related disorders. 2020;37:101450

Yann K, Jackson F, Sharaf N, Mihalova T, Talbot P, Rog D, Pace A

Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis.

Multiple sclerosis and related disorders. 2017;14:1-3

Barber NA, Ganti AK

Pulmonary toxicities from targeted therapies: a review.

Targeted oncology. 2011;6(4):235-43

Creelan B, Ferber A

A fatal case of alemtuzumab-associated interstitial pneumonitis.

American journal of therapeutics. 2008;15(1):82-4